Aurobindo Pharma has been pursuing aggressive filings of API DMFs and formulation dossiers in the US, Europe and Canada and other key markets to emerge as a significant provider of pharmaceuticals.

During 2005-06, about 75 patents have been filed for API/formulation processes taking the total cumulative patents filed to 180. About 38 DMFs have been filed, taking the cumulative filings to 67 in the US. The global filings stood at 278.

In the case of ANDAs, the company during 2005-06, has filed 32 ANDAs, taking the cumulative filings to 51 for the US. About 89 filings have been done including the US and Europe taking the cumulative filings in regulated markets to 123. The global filings stood at 537 ANDAs.

Aurobindo has achieved the transition from an API company in semi-regulated markets to a vertically integrated pharma company in both regulated and semi-regulated markets with capabilities in IPR generation, chemical research, API production and formulation to penetrate global markets.

The exports during the last fiscal were worth over Rs 860 crore, achieving a growth of 49 per cent compared to the financial year 2004-05. The exports accounted to about 58 per cent of the overall sales of the company.